Critical Reviews in Oncology / Hematology
Volume 74, Issue 2 , Pages 79-86 , May 2010

Lhermitte's sign: Review with special emphasis in oncology practice

  • Cengiz Gemici

      Affiliations

    • Corresponding Author InformationTel.: +90 532 5780702; fax: +90 216 3273374.

,Accepted 30 April 2009.

References 

  1. Marie P, Chatelin C. Note sur certains symptomes vrais amblement d’origine radiculaire chez les blessées du crane. Rev Neurol. 1917;24:143–144
  2. Lhermitte J, Bollak A, Nicholas M. Les douleurs a type de décharge électrique consécutives a la flexion céphalique dans la sclérose en plaques. Un cas de forme sensitive de la sclerose multiple. Rev Neurol. 1924;39:56–62
  3. Gutrecht JA. Lhermitte's sign. From observation to eponym. Arch Neurol. 1989;46:557–558
  4. Kempster PA, Rollinson RD. The Lhermitte phenomenon: variant forms and their significance. J Clin Neurosci. 2008;15:379–381
  5. Nordin M, Nystrom B, Wallin U, Hagbarth KE. Ectopic sensory discharges and paresthesiae in patients with disorders of peripheral nerves, dorsal roots and dorsal columns. Pain. 1984;20:231–245
  6. Esik O, Csere T, Stefanits K, et al. A review on radiogenic Lhermitte's sign. Pathol Oncol Res. 2003;9:115–120
  7. Atkinson SL, Li YQ, Wong CS. Apoptosis and proliferation of oligodendrocyte progenitor cells in the irradiated rodent spinal cord. Int J Radiat Oncol Biol Phys. 2005;62:535–544
  8. Butler WM, Taylor HG, Diehl LF. Lhermitte's sign in cobalamin (vitamin B12) deficiency. JAMA. 1981;245:1059
  9. Martin D. Lhermitte's sign and cobalamin deficiency. JAMA. 1982;247:28
  10. Sandyk R, Brennan JW. “Lhermitte's sign” as a presenting symptom of subacute combined degeneration of the cord. Ann Neurol. 1983;13:215–216
  11. Gautier-Smith PC. Lhermitte's sign in subacute combined degeneration of the cord. J Neurol Neurosurg Psychiatry. 1973;36:861–863
  12. Gutrecht JA, Zamani AA, Salgado ED. Anatomic-radiologic basis of Lhermitte's sign in multiple sclerosis. Arch Neurol. 1993;50:849–851
  13. Fritschi J, Sturzenegger M. Spinal MRI supporting myelopathic origin of early symptoms in unsuspected cobalamin deficiency. Eur Neurol. 2003;49:146–150
  14. Miller DH, McDonald WI, Blumhardt LD, et al. Magnetic resonance imaging in isolated noncompressive spinal cord syndromes. Ann Neurol. 1987;22:714–723
  15. Imai T, Tsuda E, Suzuki M, Hozuki T, Matsumoto H. Lhermitte's sign in alcoholic myelopathy without portosytemic shunting: MRI evaluation. Intern Med. 2005;44:153–154
  16. Bassi SS, Bulundwe KK, Greeff GP, Labuscagne JH, Gledhill RF. MRI of the spinal cord in myelopathy complicating vitamin B12 deficiency: two additional cases and a review of the literature. Neuroradiology. 1999;41:271–274
  17. Hodges SD, Castleberg RL, Miller T, Ward R, Thornburg C. Cervical epidural steroid injection with intrinsic spinal cord damage. Two case reports. Spine. 1998;23:2137–2142
  18. Traynelis VC, Hitchon PW, Yuh WT, Kaufman HH. Magnetic resonance imaging and posttraumatic Lhermitte's sign. J Spinal Disord. 1990;3:376–379
  19. Newton HB, Rea GL. Lhermitte's sign as a presenting symptom of primary spinal cord tumor. J Neurooncol. 1996;29:183–188
  20. Klimo P, Blumenthal DT, Couldwell WT. Congenital partial aplasia of the posterior arch of the atlas causing myelopathy: case report and review of the literature. Spine. 2003;28:E224–E228
  21. Ventafridda V, Caraceni A, Martini C, Sbanotto A, De Conno F. On the significance of Lhermitte's sign in oncology. J Neurooncol. 1991;10:133–137
  22. Esik O, Csere T, Stefanits K, et al. Increased metabolic activity in the spinal cord of patients with long-standing Lhermitte's sign. Strahlenther Onkol. 2003;179:690–693
  23. Kanchandani R, Howe JG. Lhermitte's sign in multiple sclerosis: a clinical survey and review of the literature. J Neurol Neurosurg Psy. 1982;45:308–312
  24. Al-Araji AH, Oger J. Reappraisal of Lhermitte's sign in multiple sclerosis. Mult Scler. 2005;11:389–402
  25. Solaro C, Brichetto G, Amato MP, et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology. 2004;63:919–921
  26. Arasil E, Tascioglu AO. Spontaneous migration of an intracranial bullet to the cervical spinal canal causing Lhermitte's sign. Case report. J Neurosurg. 1982;56:158–159
  27. Chan RC, Steinbok P. Delayed onset Lhermitte's sign following head and/or neck injuries. Report of four cases. J Neurosurg. 1984;60:609–612
  28. Leaver RC, Loeser JD. Lhermitte's phenomenon after high velocity missile injuries of the brain. J Neurosurg. 1971;34:159–163
  29. Merriam WF, Taylor TK, Ruff SJ, McPhail MJ. A reappraisal of acute traumatic central cord syndrome. J Bone Joint Surg Br. 1986;68:708–713
  30. Vollmer TL, Brass LM, Waxman SG. Lhermitte's sign in a patient with herpes zoster. J Neurol Sci. 1991;106:153–157
  31. Falga-Tirado C, Ordi-Ros J, Perez-Peman P, Cucurull-Canosa E, Bosch-Gil J. Lhermitte's sign in Behcet's disease. Br J Rheumatol. 1995;34:184–185
  32. Page NG, Spiteri MA. Lhermitte's sign in Behcet's disease. Br Med J (Clin Res Ed). 1982;284:704–705
  33. Falga-Tirado C, Ordi-Ros J, Cucurull-Canosa E, Soler-Ferrer C. Lhermitte's sign in systemic lupus erythematosus. Lupus. 1995;4:327
  34. Lunsford JM, Wynn MH, Kwan WH. Nitrous oxide-induced myeloneuropathy. J Foot Surg. 1983;22:222–225
  35. Layzer RB. Myeloneuropathy after prolonged exposure to nitrous oxide. Lancet. 1978;2:1227–1230
  36. Blanco G, Peters HA. Myeloneuropathy and macrocytosis associated with nitrous oxide abuse. Arch Neurol. 1983;40:416–418
  37. Murphy DK, Gutrecht JA. Lhermitte's sign in cavernous angioma of the cervical spinal cord. J Neurol Neurosurg Psychiatry. 1998;65:954–955
  38. Palace J. Making the diagnosis of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001;71(Suppl. 2):ii3–ii8
  39. St Clair WH, Arnold SM, Sloan AE, Regine WF. Spinal cord and peripheral nerve injury: current management and investigations. Sem Radiat Oncol. 2003;13:322–332
  40. Delattre JY, Rosenblum MK, Thaler HT, Mandell L, Shapiro WR, Posner JB. A model of radiation myelopathy in the rat. Pathology, regional capillary permeability changes and treatment with dexamethasone. Brain. 1988;111:1319–1336
  41. Leung WM, Tsang NM, Chang FT, Lo FT. Lhermitte's sign among nasopharyngeal cancer patients after radiotherapy. Head Neck. 2005;27:187–194
  42. Fein DA, Marcus RB, Parsons JT, Mendenhall WM, Million RR. Lhermitte's sign: incidence and treatment variables influencing risk after irradiation of the cervical spinal cord. Int J Radiat Oncol Biol Phys. 1993;27:1029–1033
  43. Marcus RB, Million RR. The incidence of myelitis after irradiation of the cervical spinal cord. Int J Radiat Oncol Biol Phys. 1990;19:3–8
  44. Keime-Guibert F, Napolitano M, Delattre JY. Neurological complications of radiotherapy and chemotherapy. J Neurol. 1998;245:695–708
  45. Tuxen MK, Hansen SW. Neurotoxicity secondary to antineoplastic agents. Cancer Treat Rev. 1994;20:191–214
  46. Dropcho EJ. Neurotoxicity of cancer chemotherapy. Semin Neurol. 2004;24:419–426
  47. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006;33:15–49
  48. Sul JK, DeAngelis LM. Neurologic complications of cancer chemotherapy. Semin Oncol. 2006;33:324–332
  49. Eeles R, Tait DM, Peckham MJ. Lhermitte's sign as a complication of cisplatin-containing chemotherapy for testicular cancer. Cancer Treat Rep. 1986;70:905–907
  50. Inbar M, Merimsky O, Wigler N, Chaitchik S. Cisplatin-related Lhermitte's sign. Anticancer Drugs. 1992;3:375–377
  51. Dewar J, Lunt H, Abernethy DA, Dady P, Haas LF. Cisplatin neuropathy with Lhermitte's sign. J Neurol Neurosurg Psychiatry. 1986;49:96–99
  52. Walther PJ, Rossitch E, Bullard DE. The development of Lhermitte's sign during cisplatin chemotherapy. Possible drug-induced toxicity causing spinal cord demyelination. Cancer. 1987;60:2170–2172
  53. Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer. 1990;66:1117–1123
  54. List AF, Kummet TD. Spinal cord toxicity complicating treatment with cisplatin and etoposide. Am J Clin Oncol. 1990;13:256–258
  55. Hilkens PH, Verweij J, Stoter G, Vecht CJ, van Putten WL, van den Bent MJ. Peripheral neurotoxicity induced by docetaxel. Neurology. 1996;46:104–108
  56. Van den Bent MJ, Hilkens PH, Sillevis Smitt PA, van Raaij-van den Aarssen VJ, Bontenbal M, Verweij J. Lhermitte's sign following chemotherapy with docetaxel. Neurology. 1998;50:563–564
  57. Taieb S, Trillet-Lenoir V, Rambaud L, Descos L, Freyer G. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer. 2002;94:2434–2440
  58. Ciucci G, De Giorgi U, Leoni M, Bianchedi G. Lhermitte's sign following oxaliplatin-containing chemotherapy in a cisplatin-pretreated ovarian cancer patient. Eur J Neurol. 2003;10:328–329
  59. Walsh TJ, Clark AW, Parhad IM, Green WR. Neurotoxic effects of cisplatin therapy. Arch Neurol. 1982;39:719–720
  60. Brienza S, Vignoud J, Itzhaki M. Oxaliplatin: global safety in 682 patients. Proc Am Soc Clin Oncol. 1995;14:209
  61. Jurado JM, Pajares B, Olmos D, Sevilla I, Alba E. ‘Out of blue’ Lhermitte's sign: three cases due to low cumulative doses of oxaliplatin. Ann Oncol. 2008;19:2093–2094
  62. Heinzlef O, Lotz JP, Roullet E. Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry. 1998;64:667–669
  63. Wen PY, Blanchard KL, Block CC, et al. Development of Lhermitte's sign after bone marrow transplantation. Cancer. 1992;69:2262–2266
  64. Denis F, Garaud P, Bardet E, et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys. 2003;55:93–98
  65. de Brabander C, Cornelissen J, Smitt PA, Vecht CJ, van den Bent MJ. Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors. J Neurol Neurosurg Psychiatry. 2000;68:36–40
  66. Rosenfeld MR, Pruitt A. Neurologic complications of bone marrow, stem cell, and organ transplantation in patients with cancer. Semin Oncol. 2006;33:352–361
  67. Baldwin RN, Chadwick D. Lhermitte's sign due to thoracic cord compression. J Neurol Neurosurg Psychiatry. 1986;49:840–841
  68. Rogers LR. Thoracic cord compression from metastatic prostate carcinoma with Lhermitte's sign. J Neurol Neurosurg Psychiatry. 1987;50:1086
  69. Lewanski CR, Sinclair J, Stewart JSW. Lhermitte's sign following head and neck radiotherapy. Clin Oncol (R Coll Radiol). 2000;12:98–103
  70. Glantz MJ, Burger PC, Friedman AH, Radtke RA, Massey EW, Schold SC. Treatment of radiation induced nervous system injury with heparin and warfarin. Neurology. 1994;44:2020–2027
  71. Calabro F, Jinkins JR. MRI of radiation myelitis: a report of a case treated with hyperbaric oxygen. Eur Radiol. 2000;10:1079–1084

☆ The study has not been presented elsewhere, either as a whole or in part.

PII: S1040-8428(09)00100-0

doi: 10.1016/j.critrevonc.2009.04.009

Critical Reviews in Oncology / Hematology
Volume 74, Issue 2 , Pages 79-86 , May 2010

Article Tools